GRI Bio says Phase 2a trial shows GRI-0621 lifts placebo-adjusted FVC in IPF patients at 12 weeks

GRI Bio disclosed new Phase 2a data on GRI-0621 in idiopathic pulmonary fibrosis, already presented at ERS 2026.

• Results supported a consistent biological effect aligned with reduced fibrosis activity, tissue repair signals, improved symptoms, and stable lung function.
• Patients on GRI-0621 were more likely to show improved lung function versus placebo, supporting continued development despite exploratory endpoints.
• Safety profile appeared manageable over 12 weeks, with fewer key tolerability complaints than placebo in this small study.